JPRN-UMIN000010911已完成2 期
Efficacy and safety of sitafloxacin (STFX) for low-risk febrile neutropenia in patients with lung cancer, phase II study, - STFX for low risk febrile neutropenia
ung Oncology Group in Kyushu, Japan (LOGIK)0 个研究点目标入组 54 人开始时间: 2013年6月12日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patient who is too severely ill 2. A history of renal failure (S-Cr of 2.0 mg/dl or above) 3. A known history of hypersensitivity to fluoroquinolones 4. A known history of allergy 5. Patient who is not evaluated for response 6. Pregnant or lactating women. 7. Patients administered with prohibiting medication (such as other antibiotics, gamma-globulin, corticosteroid) 8.patient who is judged as an inappropriate case by the doctor in charge
研究者
相似试验
已完成
不适用
Efficacy and safety of sitafloxacin (STFX) in tonsillar abcess; prospective study in outpatient setting.peritonsillar abcessJPRN-UMIN000013812Saitama Medical University20
招募中
不适用
Efficacy of sitafloxacin for urinary tract infectioJPRN-jRCTs061200052Takehiro Iwata92
已完成
不适用
Evaluation of efficacy of Sitafloxacin in treatment of moderate to severe acute rhinosinusitisacute rhinosinusitisJPRN-UMIN000009567Wakayama-Okayama Otolaryngology Pharma100
已完成
不适用
clinical efficacy of sitafloxacin( 200mg daily)against female patients with acute cystitisAcute cystitisJPRN-UMIN000009852Jikei university katsushika medical center,Department of urology100
已完成
2 期
Efficacy of sitafloxacin as third-line eradication treatment of Helicobacter pyloriH. pylori infectionJPRN-UMIN000004778ational Organization Tokyo medical center30